Federal Register #2026-06283

Exclusive Patent License for PEDF Peptide Therapeutics for Retinal Degeneration

This opportunity involves the National Eye Institute's intent to grant an exclusive patent license for PEDF peptide therapeutics: - Government Buyer: - National Eye Institute, part of the National Institutes of Health under the Department of Health and Human Services - OEMs and Vendors: - Perpetual Biosciences, Inc. (prospective licensee) - U.S. Government (patent assignee) - Products/Services Requested: - Exclusive patent license for peptide therapeutics derived from Pigment Epithelium-Derived Factor (PEDF) peptides - Technology targets treatment of human ophthalmological diseases including: - Retinitis pigmentosa - Glaucoma - Age-related macular degeneration - Patent coverage includes multiple U.S. and international applications and issued patents - Unique/Notable Requirements: - License is exclusive, worldwide, and royalty-bearing - Focus is on peptide therapeutics for neurodegenerative ophthalmic diseases - Opportunity is for patent licensing, not product procurement - Public comments or competing license applications are invited - Place of Performance/Contracting Office: - National Eye Institute, NIH, HHS - New York, NY (location of Perpetual Biosciences, Inc.)

Description

The National Eye Institute, part of the National Institutes of Health, is considering granting an exclusive patent license to Perpetual Biosciences, Inc. for inventions related to PEDF peptides used in treating retinal degeneration. The license covers various patent applications and issued patents worldwide, focusing on peptide therapeutics for ophthalmological diseases such as retinitis pigmentosa, glaucoma, and age-related macular degeneration. Interested parties may submit written comments or license applications by April 16, 2026.

View original listing